OBJECTIVES

: This analysis aimed to compare the cost per response of secukinumab 150 and 300 mg versus adalimumab, etanercept and infliximab for treatment of psoriatic arthritis. Lower cost per response of a drug compared to another drug, enables treatment of greater number of patients with a given budget using that drug.

METHODS

: Response consisted of achieving the American College of Rheumatology (ACR 20/50/70) outcomes in a biologic-naïve population and was derived from a matching-adjusted indirect comparison (MAIC) conducted with FUTURE-2, ADEPT, NCT00317499 2004 trial and IMPACT-2 clinical trials. MAIC data was available up to 24 weeks for etanercept and up to 48 weeks for adalimumab and infliximab. The cost per response for each treatment was calculated as the cost of treatment divided by the number of responders achieving each ACR outcome. List price (2018) of drugs were obtained from the Saudi Food and Drug Authority website. The overall drug cost per treatment was calculated by multiplying drug cost per dose by the number of doses required during the treatment period. Sensitivity analysis was conducted to confirm robustness of analysis.

RESULTS

: Secukinumab 150mg and 300mg achieved greater ACR 20/50/70 response rates against all biologics. The cost per response for secukinumab 150mg was lower for ACR 20/50/70 outcomes compared to the other biologics: SR56,928/SR79,361/SR139,861 for secukinumab 150mg and SR122,771/SR158,169/SR231,946 for adalimumab; SR37,093/SR51,887/SR90,329 for secukinumab 150mg and SR59,250/SR76,379/SR322,320 for etanercept; SR51,729/SR101,150/SR208,825 for secukinumab 150mg and SR144,516/SR231,935/SR383,423 for infliximab. The cost per response for secukinumab 300mg was lower for ACR 50/70, ACR 70 and ACR 20/50/70 compared to adalimumab, etanercept and infliximab respectively. Sensitivity analysis confirmed robustness of the analysis.

CONCLUSIONS

: Treatment with secukinumab for psoriatic arthritis is efficient, allowing for more responders at lower costs with secukinumab versus other biologics with a given budget in Saudi Arabia.